Navigation Links
Signal Genetics LLC Announces Update to MyPRS™ Gene Expression Profiling Assay for Multiple Myeloma
Date:7/22/2013

(PRWEB) July 22, 2013

Signal Genetics today announced that it has launched an update to its MyPRS gene expression assay for patients with Multiple Myeloma, which will improve patient prognoses, enable better informed patient care decisions, and ultimately reduce costs.

Every MyPRS test performed now includes an analysis of an additional set of 813-genes within the patient’s genome, which is used to create an individualized ‘Virtual Karyotype’ view of the patient’s disease. This new algorithm is offered in conjunction with the GEP70 risk stratification signature and 7-class molecular subtyping algorithm. The combination of multiple genetic profiles provides the physician with an unparalleled level of personalized information about each patient, and represents the results of decades of research at the University of Arkansas for Medical Sciences (UAMS).

The Virtual Karyotype algorithm, published in Blood (May 24, 2012 vol. 119 no. 21 e148-e150), predicts cytogenetic abnormalities in patients with multiple myeloma using gene expression profiling (GEP) . The accuracy of the method was validated against a range of conventional cytogenetic techniques and was shown to have an accuracy of up to 89 percent. Certain cytogenetic abnormalities, that are a hallmark of Multiple Myeloma, are commonly used as clinical parameters for determining the disease stage and help guide therapy decisions for patients. The Virtual Karyotype algorithm, now included in MyPRS, was designed to be an alternative to conventional methods which can be time consuming, expensive, subjective and often fail due to the difficulties encountered when attempting to culture myeloma cells.

Sam Riccitelli, President and CEO of Signal Genetics said, “We are thrilled that our ongoing relationship with UAMS allows us to bring new developments in the genetic understanding of Multiple Myeloma to physicians and patients throughout the country. The addition of the Virtual Karyotype signature to our MyPRS assay is a major advancement in expanding the already proven clinical utility of GEP for patients with myeloma and should encourage even more physicians to incorporate the test into routine care.”

About MyPRS
MyPRS, developed by UAMS, has been marketed by Signal Genetics since 2011. The multi-gene test, performed on bone marrow aspirate material, has been incorporated into the routine management of patients diagnosed with Multiple Myeloma in numerous treatment centers across the country. MyPRS™ can be used at the time of initial myeloma diagnosis or if the patient has experienced a relapse of their disease.

About Signal Genetics
Signal Genetics LLC is a privately held molecular diagnostic company based in New York, NY and Little Rock, AR focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. For more information, visit https://www.signalgenetics.com or email info(at)signalgenetics(dot)com.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10944110.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Signal-Health Develops Easy Checklist to Identify Possible Sweating Issues in Horses
2. Researchers identify signals that direct the immune system to reject a transplanted organ
3. Laser-like photons signal major step towards quantum Internet
4. Physicists skirt thermal vibration, transfer optical signal via mechanical oscillator
5. Needle beam could eliminate signal loss in on-chip optics
6. Todays Technical View: Elan Corp., Amarin, Seattle Genetics, and Cubist Pharma
7. GeneTex Introduces New Mouse Monoclonal Antibody Against the Ten-Eleven Translocation 1 (TET1) Protein for DNA Methylation/Epigenetics Research
8. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
9. Epigenetics: Changing the Way We Think about DNA
10. Research and Markets: Cytogenetics - Technologies, Markets and Companies - 2013
11. Plunketts Biotech & Genetics Industry Almanac 2013: Biotech & Genetics Industry Market Research, Statistics, Trends & Leading Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2019)... ... July 08, 2019 , ... Today, at the BIO World Congress ... Association (NCGA) announced the winners of the Consider Corn Challenge II. Three winners ... field corn to produce biobased materials. , “Corn is a sustainable, abundant and ...
(Date:7/2/2019)... ... 2019 , ... Leading Regenerative Veterinary Medicine company, VetStem Biopharma , was ... The film focuses on regenerative veterinary medicine as a means of improving the quality ... in the Brentwood and Pacific Palisades International Film Festival in Los Angeles, California ...
(Date:6/18/2019)... ... June 17, 2019 , ... IVERIC ... into an agreement for production and manufacturing of GMP-grade adeno-associated virus (AAV) vector ... autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for the treatment of BEST1 related ...
(Date:6/12/2019)... ... June 12, 2019 , ... ... leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries, ... been signed. The agreement will grant exclusive rights for Zillion to represent LDA ...
Breaking Biology Technology:
(Date:6/11/2019)... ... June 10, 2019 , ... Improved Pharma LLC announces the ... issue of AAPS PharmSciTech. The article was published online on April 29th, 2019. The ... along with Xiaoming Sean Chen of Purdue University. , The article is the most ...
(Date:6/6/2019)... CHICAGO (PRWEB) , ... June 05, 2019 , ... ... its role as the exclusive financial advisor to Pathologists Bio-Medical Laboratories (PBM) on ... is a preeminent anatomic pathology platform that provides services to more than one ...
(Date:6/4/2019)... ... June 04, 2019 , ... Harper was three years old when her owners ... dysplasia, which caused painful osteoarthritis in the joints. She was referred to a ... , The surgical specialist, Dr. Christopher Eich of Southern California Veterinary Specialty Hospital ...
Breaking Biology News(10 mins):